Receive a complete Daily History of this Stock You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file in ASCII format within a few hours or ordering. Product Details | Order

Business Description
ImClone Systems Incorporated is a biopharmaceutical company involved in advance oncology care by developing a portfolio of targeted biologic treatments designed to address the medical needs of patients with cancer. It focuses on three strategies for treating cancer: growth factor blockers, angiogenesis inhibitors and cancer vaccines. The Company's lead product, ERBITUX (Cetuximab), is an antibody which has been approved by the United States Food and Drug Administration (FDA) for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy, and for use as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy.

Financial Information
For the nine months ended 9/30/04, revenues totalled $276 million, up from $61 million. Net income totalled $126.8 million vs. a loss of $86.2 million. Results reflect increased license fees and milestone revenues.